Aarhus University Seal / Aarhus Universitets segl

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

BACKGROUND: Mutated circulating cell-free DNA (cfDNA) has been suggested as a surrogate marker of tumour burden and aggressiveness of disease. We examined the association between the level of plasma mutant cfDNA and metabolic tumour burden (MTB) measured by (18)F-fluoro-D-glucose positron emission tomography/computed tomography ((18)F-FDG PET/CT). Furthermore, the presence of mutant cfDNA was correlated with patient survival.

METHODS: Forty-six advanced non-small cell lung cancer (NSCLC) patients were included. At the time of inclusion, blood sampling and a PET/CT scan were performed. cfDNA was isolated and next-generation sequencing (NGS) was performed (Ion AmpliSeq Colon and Lung Cancer panel v2). MTB was defined by a volumetric PET parameter.

RESULTS: NGS succeeded in 41 patients. Mutations were detected in the blood of 24 patients. A significant correlation between the allele frequency of the most frequent mutation and MTB was found (P=0.001). Patients with detectable mutated cfDNA had a significantly shorter median overall survival compared with patients without (3.7 versus 10.6 months, P=0.019). This impact on survival was independent of the MTB.

CONCLUSIONS: Level of mutated cfDNA tends to correlate with MTB in advanced-stage NSCLC patients. Patients with detectable mutant DNA in plasma had an inferior survival, indicating that this could be an important predictor of survival.

Original languageEnglish
JournalB J C
Volume117
Issue5
Pages (from-to)704-709
Number of pages6
ISSN0007-0920
DOIs
Publication statusPublished - 22 Aug 2017

    Research areas

  • Aged, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, DNA, Neoplasm, Female, Fluorodeoxyglucose F18, Gene Frequency, Glycolysis, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals, Retrospective Studies, Survival Rate, Journal Article

See relations at Aarhus University Citationformats

ID: 118536044